Clinical trial

IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma

NCT02614833

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2015-12-01

PhasePHASE2

Study timeline

Study start (unknown)2015-12-01Date precision: month

Registry last updated2021-10-05

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Adenocarcinoma Breast Stage IVunresolved

Interventions

IMP321 (eftilagimod alpha)BIOLOGICAL

PlaceboDRUG

PaclitaxelDRUG · verified · RxNorm: paclitaxel

Sponsors & collaborators

Immutep S.A.S.lead sponsor

Mapped research locations

BudapestHungary2 ToulouseFrance1 BrusselsBelgium1 ManchesterUnited Kingdom1 LeuvenBelgium1 AmsterdamNetherlands1 EssenGermany1 HeidelbergGermany1 FrankfurtGermany1 GroningenNetherlands1 RotterdamNetherlands1 UlmGermany1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02614833 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.